Complete Filing Data
Jin Medical International Ltd. reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of $29.57 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Jin Medical International Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | $1.2M | $3.7M | $2.9M | $2.7M | $2.6M |
| Cost of Revenue * | $14.6M | $14.0M | $13.0M | $13.0M | $14.4M |
| Revenues | $20.7M | $23.5M | $19.8M | $19.2M | $20.8M |
| Research And Development Expense | $1.6M | $1.5M | $1.5M | $1.9M | $1.6M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$361.2K | $841.5K | -$493.2K | -$1.5M | $594.7K |
| Operating Income Loss | $608.2K | $3.6M | $2.9M | $2.1M | $2.6M |
| Operating Expenses | $5.4M | $5.9M | $3.9M | $4.1M | $3.7M |
| Income Tax Expense Benefit | $214.6K | $763.9K | $343.7K | $36.1K | $248.6K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | $1.6M | $4.2M | $3.2M | $2.7M | $2.9M |
| Gross Profit | $6.0M | $9.5M | $6.8M | $6.2M | $6.4M |
| General And Administrative Expense | $2.5M | $3.3M | $1.9M | $1.8M | $1.7M |
| Deferred Income Tax Expense Benefit | -$22.1K | $36.3K | $89.6K | -$86.0K | -$1.7K |
| Comprehensive Income Net Of Tax | $823.5K | $4.5M | $2.4M | $1.2M | $3.2M |
| Deferred Income Tax Assets Net | $141.8K | $121.3K | $152.5K | $245.2K | |
| Other Nonoperating Income | $175.5K | $105.2K | $222.4K | $244.1K | |
| Nonoperating Income Expense | $987.6K | $545.0K | $354.7K | $612.1K | |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | $1.0M | $4.3M | $2.4M | $1.2M | |
| Income Taxes Paid Net | $564.8K | $205.4K | $142.7K | $47.4K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity * | $29.6M | $28.8M | $24.0M | $15.2M | $14.0M | $10.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $7.5M | $8.1M | $6.9M | $4.8M | $3.7M | $1.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$674.5K | $1.2M | $2.1M | $1.1M | $2.0M | |
| Taxes Payable Current | $302.3K | $1.1M | $271.4K | $248.1K | ||
| Short Term Investments | $22.2M | $18.6M | $9.8M | $2.3M | ||
| Retained Earnings Accumulated Deficit | $20.9M | $20.0M | $16.9M | $14.4M | ||
| Property Plant And Equipment Net | $7.9M | $1.5M | $1.5M | $1.6M | ||
| Prepaid Expense And Other Assets Current | $3.7M | $2.3M | $892.6K | $989.3K | ||
| Liabilities Current | $23.8M | $17.2M | $8.9M | $5.7M | ||
| Liabilities And Stockholders Equity | $53.4M | $45.8M | $32.9M | $20.9M | ||
| Liabilities | $23.8M | $17.2M | $8.9M | $5.7M | ||
| Inventory Net | $4.9M | $5.2M | $5.1M | $6.7M | ||
| Common Stock Value | $7.8K | $7.8K | $7.8K | $6.8K | ||
| Assets Current | $44.1M | $42.8M | $31.1M | $18.9M | ||
| Assets | $53.4M | $45.8M | $32.9M | $20.9M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$924.0K | -$556.2K | -$1.4M | -$911.1K | ||
| Accounts Payable Current | $3.3M | $3.0M | $3.4M | $4.1M | ||
| Gain Loss On Sale Of Property Plant Equipment | -$36.7K | -$2.6K | $6.9K | -$13.4K | ||
| Operating Lease Right Of Use Asset | $85.2K | $256.1K | $154.4K | $163.2K | ||
| Accounts Receivable Net Current | $5.8M | $5.9M | $3.3M | $3.8M | ||
| Repayments Of Short Term Debt | $11.4M | $5.6M | $1.4M | $3.5M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Proceeds From Sale Of Short Term Investments | $6.0M | $12.7M | $4.4M | $5.2M | $4.1M |
| Payments To Acquire Short Term Investments | $9.7M | $21.1M | $12.1M | $5.6M | $5.0M |
| Payments To Acquire Property Plant And Equipment | $6.6M | $144.9K | $113.9K | $40.2K | $42.9K |
| Net Cash Provided By Used In Operating Activities | $2.9M | -$1.2M | $3.1M | $1.6M | $5.8M |
| Net Cash Provided By Used In Investing Activities | -$10.8M | -$9.5M | -$7.7M | -$120.9K | -$1.1M |
| Net Cash Provided By Used In Financing Activities | $7.4M | $11.7M | $6.9M | $121.9K | -$2.9M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $770.9K | $1.4M | $716.4K | -$430.7K | $810.9K |
| Increase Decrease In Inventories | -$168.3K | -$80.3K | -$1.6M | $504.4K | -$458.6K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $245.9K | $97.2K | -$67.7K | -$281.2K | $34.7K |
| Increase Decrease In Accrued Income Taxes Payable | -$793.6K | $820.0K | $30.5K | $155.5K | -$95.3K |
| Increase Decrease In Accounts Receivable | -$1.3M | $2.4M | -$348.7K | -$241.9K | -$159.4K |
| Increase Decrease In Accounts Payable | $287.0K | -$499.6K | -$646.9K | -$810.3K | -$369.1K |
| Depreciation Depletion And Amortization | $243.4K | $237.8K | $225.9K | $362.6K | $346.6K |
| Proceeds From Repayments Of Related Party Debt | -$134.1K | $4.5M | -$4.5M | $121.9K | -$103.9K |
| Proceeds From Short Term Debt | $19.0M | $12.4M | $5.7M | $768.0K | |
| Proceeds From Sale Of Property Plant And Equipment | $444.00 | $348.00 | $10.1K | ||
| Increase Decrease In Contract With Customer Liability | -$163.6K | -$65.5K | -$102.9K | -$755.4K | |
| Increase Decrease In Accounts Receivable Related Parties | -$989.9K | $1.5M | $724.8K | -$91.7K | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$139.6K | $273.6K | -$149.9K | -$461.2K | |
| Increase Decrease In Contract With Customer Liability Related Parties | -$7.7K | $1.7K | $123.2K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 156.5M | 156.5M | 145.1M | 135.0M | 135.0M |
| Weighted Average Number Of Diluted Shares Outstanding | 156.5M | 156.5M | 145.1M | 135.0M | 135.0M |
| Earnings Per Share Diluted | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 |
| Earnings Per Share Basic | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 |
| Common Stock Shares Authorized | 1.00B | 1.00B | 1.00B | 1.00B | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 156.5M | 155.9M | 155.9M | 135.0M | |
| Common Stock Shares Issued | 156.5M | 155.9M | 155.9M | 135.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Selling Expense | $1.3M | $1.1M | $453.3K | $402.0K | $489.0K |
| Provision For Doubtful Accounts | $71.8K | -$47.5K | $120.3K | $28.9K | -$108.7K |
| Foreign Currency Transaction Gain Loss Before Tax | $23.1K | -$26.8K | -$50.4K | $186.4K | $63.4K |
| Business And Sales Related Tax | $198.3K | $107.1K | $180.1K | $159.5K | $225.1K |
| Interest Paid Net | $411.1K | $239.4K | $5.3K | $47.4K | $302.3K |
| Short Term Borrowings | $18.8M | $11.3M | $4.1M | ||
| Statutory Accounting Practices Statutory Capital And Surplus Balance | $2.9M | $2.6M | $2.0M | $1.7M | |
| Investment Income Interest | $789.1K | $466.5K | $182.7K | $181.6K | |
| Additional Paid In Capital | $6.7M | $6.4M | $79.8K | ||
| Stock Issued During Period Value New Issues | $312.0K | $8.0M |
Most recent annual filing with the SEC: February 10, 2026
Data sourced from SEC EDGAR public filings as of August 7, 2026.